Joint Formulary & PAD

Rimegepant - Migraine (prevention)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Oral lyophilisates
Associated Icons :
Restrictions / Comments :
Documents :
 

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Rimegepant
Indication :
Migraine (prevention)
Group Name :
Keywords :
calcitonin gene-related peptide inhibitors, anti-CGRP antagonists, migraine prevention, episodic migraine
Brand Names Include :
Vydura
Important Information :
For episodic migraine only
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
2

Other Indications

Below are listed other indications that Rimegepant is used to treat.

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves rimegepant  in line with the recommendations made in NICE TA906, for  preventing migraine.

Rimegepant for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.